BlackRock
CTMX icon

BlackRock’s CytomX Therapeutics CTMX Stock Holding History

BlackRock’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.6M Buy
5,228,280
+1,558,887
+42% +$7.91M ﹤0.01% 2948
2025
Q4 		$15.6M Buy
3,669,393
+1,287,481
+54% +$4.89M ﹤0.01% 3221
2025
Q3 		$7.6M Sell
2,381,912
-6,541
-0.3% -$14.7K ﹤0.01% 3587
2025
Q2 		$5.42M Buy
2,388,453
+1,222,069
+105% +$1.97M ﹤0.01% 3736
2025
Q1 		$742K Sell
1,166,384
-73,394
-6% -$56.9K ﹤0.01% 4278
2024
Q4 		$1.28M Buy
1,239,778
+71,212
+6% +$76.6K ﹤0.01% 4166
2024
Q3 		$1.38M Buy
1,168,566
+29,537
+3% +$37.5K ﹤0.01% 4099
2024
Q2 		$1.39M Buy
1,139,029
+7,821
+0.7% +$15.6K ﹤0.01% 4079
2024
Q1 		$2.47M Sell
1,131,208
-4,927
-0.4% -$9.09K ﹤0.01% 3934
2023
Q4 		$1.76M Sell
1,136,135
-3,501
-0.3% -$4.6K ﹤0.01% 4086
2023
Q3 		$1.47M Sell
1,139,636
-8,180
-0.7% -$12.9K ﹤0.01% 4107
2023
Q2 		$1.97M Buy
1,147,816
+24,044
+2% +$39.9K ﹤0.01% 4058
2023
Q1 		$1.7M Sell
1,123,772
-176,229
-14% -$398K ﹤0.01% 4122
2022
Q4 		$2.08M Sell
1,300,001
-499,362
-28% -$739K ﹤0.01% 4115
2022
Q3 		$2.61M Sell
1,799,363
-27,228
-1% -$41.9K ﹤0.01% 4055
2022
Q2 		$3.34M Sell
1,826,591
-3,165,503
-63% -$6.06M ﹤0.01% 3998
2022
Q1 		$13.3M Buy
4,992,094
+29,732
+0.6% +$114K ﹤0.01% 3422
2021
Q4 		$21.5M Sell
4,962,362
-90,239
-2% -$529K ﹤0.01% 3233
2021
Q3 		$25.7M Sell
5,052,601
-28,022
-0.6% -$150K ﹤0.01% 3114
2021
Q2 		$32.2M Sell
5,080,623
-108,082
-2% -$842K ﹤0.01% 3004
2021
Q1 		$40.1M Buy
5,188,705
+1,383,526
+36% +$11M ﹤0.01% 2768
2020
Q4 		$24.9M Sell
3,805,179
-301,548
-7% -$2.15M ﹤0.01% 2894
2020
Q3 		$27.3M Sell
4,106,727
-30,582
-0.7% -$227K ﹤0.01% 2686
2020
Q2 		$34.5M Buy
4,137,309
+196,531
+5% +$1.83M ﹤0.01% 2469
2020
Q1 		$30.2M Sell
3,940,778
-75,270
-2% -$525K ﹤0.01% 2380
2019
Q4 		$33.4M Sell
4,016,048
-1,535
-0% -$10.4K ﹤0.01% 2592
2019
Q3 		$29.6M Buy
4,017,583
+127,534
+3% +$1.26M ﹤0.01% 2590
2019
Q2 		$43.6M Buy
3,890,049
+25,658
+0.7% +$269K ﹤0.01% 2396
2019
Q1 		$41.5M Buy
3,864,391
+3,463
+0.1% +$51.2K ﹤0.01% 2377
2018
Q4 		$58.3M Sell
3,860,928
-7,638
-0.2% -$113K ﹤0.01% 2149
2018
Q3 		$71.6M Buy
3,868,566
+642,165
+20% +$14.6M ﹤0.01% 2185
2018
Q2 		$73.8M Buy
3,226,401
+716,096
+29% +$18.3M ﹤0.01% 2128
2018
Q1 		$71.4M Sell
2,510,305
-136,294
-5% -$3.89M ﹤0.01% 2052
2017
Q4 		$55.9M Buy
2,646,599
+586,698
+28% +$12.2M ﹤0.01% 2220
2017
Q3 		$37.4M Buy
2,059,901
+247,389
+14% +$3.86M ﹤0.01% 2457
2017
Q2 		$28.1M Buy
1,812,512
+800,528
+79% +$12.1M ﹤0.01% 2583
2017
Q1 		$17.5M Buy
1,011,984
+1,002,351
+10,405% +$13.2M ﹤0.01% 2831
2016
Q4 		$106K Buy
9,633
+289
+3% +$3.5K ﹤0.01% 2508
2016
Q3 		$146K Buy
9,344
+1,759
+23% +$21.3K ﹤0.01% 2362
2016
Q2 		$77K Buy
7,585
+7,479
+7,056% +$85.3K ﹤0.01% 2695
2016
Q1 		$1K Buy
+106
New +$1.47K ﹤0.01% 3514

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock's CTMX Position: Q1 2026 in Review

BlackRock increased its CytomX Therapeutics (CTMX) stake by 42% in Q1 2026, buying an estimated $7.91M and bringing the position to 5,228,280 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2948.

BlackRock first reported a position in CTMX in Q1 2016 and has held it in 41 quarters since. The position peaked at $73.8M in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • BlackRock held 5,228,280 shares of CytomX Therapeutics worth $24.6M as of Q1 2026.
  • BlackRock bought 1,558,887 CytomX Therapeutics shares in Q1 2026, an estimated $7.91M.
  • CytomX Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2948 holding.
  • BlackRock first reported a position in CytomX Therapeutics in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's CytomX Therapeutics position peaked at $73.8M in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.